Thermo Fisher Scientific's MyeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing To Quickly Match Patients With Appropriate Trials Across North America
Thermo Fisher Scientific's MyeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing To Quickly Match Patients With Appropriate Trials Across North America
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America
myeloMATCH精準醫學臨床試驗利用次日基因組測序技術快速將患者與適當的試驗匹配在北美範圍內
To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients' bone marrow and blood for certain genetic biomarkers using Thermo Fisher's next-generation sequencing (NGS) technology, clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.
爲了加速急性髓性白血病（AML）和骨髓增生異常綜合症（MDS）新治療方法的研究，全球科學服務領導者Thermo Fisher Scientific（紐交所：TMO）正在與NCI（美國國家衛生研究院的組成部門）合作，開展myeloMATCH（分子分析用於治療選擇）精準醫學傘形試驗。通過利用Thermo Fisher的下一代測序（NGS）技術測試患者的骨髓和血液中的某些基因生物標誌物，臨床醫生可以更快地將患者與測試針對樣本中存在的特定突變的治療方案的適當臨床試驗相匹配。
譯文內容由第三人軟體翻譯。